Open access · CC-BY
via OpenAlex
A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor
Judith Giroud‐Gerbetant, Magali Joffraud, Maria Pilar Giner, Angelique Cercillieux, Simona Bártová, Mikhail V. Makarov, Ruben Zapata Perez, José L. Sánchez-García, Riekelt H. Houtkooper, Marie E. Migaud, Sofia Moco, Carles Cantó
Molecular Metabolism · 2019 · ▲ 132 citations
Abstract
A decay in intracellular NAD+ levels is one of the hallmarks of physiological decline in normal tissue functions. Accordingly, dietary supplementation with NAD+ precursors can prevent, alleviate, or even reverse multiple metabolic complications and age-related disorders in diverse model organisms. Within the constellation of NAD+ precursors, nicotinamide riboside (NR) has gained attention due to its potent NAD+ biosynthetic effects in vivo while lacking adverse clinical effects. Nevertheless, NR is not stable in circulation, and its utilization is rate-limited by the expression of nicotinamide riboside kinases (NRKs). Therefore, there is a strong interest in identifying new effective NAD+ precursors that can overcome these limitations. Through a combination of metabolomics and pharmacological approaches, we describe how NRH, a reduced form of NR, serves as a potent NAD+ precursor in mammalian cells and mice. NRH acts as a more potent and faster NAD+ precursor than NR in mammalian cells and tissues. Despite the minor structural difference, we found that NRH uses different steps and enzymes to synthesize NAD+, thus revealing a new NRK1-independent pathway for NAD+ synthesis. Finally, we provide evidence that NRH is orally bioavailable in mice and prevents cisplatin-induced acute kidney injury. Our data identify a new pathway for NAD+ synthesis and classify NRH as a promising new therapeutic strategy to enhance NAD+ levels.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.molmet.2019.09.013
- Canonical
- link ↗
- Fetched
- 2026-10-30 MST
Cite this
APA
Giroud‐Gerbetant, J., Joffraud, M., Giner, M.P., Cercillieux, A., Bártová, S., Makarov, M.V., Perez, R.Z., Sánchez-García, J.L., Houtkooper, R.H., Migaud, M.E., Moco, S., & Cantó, C. (2019). A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor. <em>Molecular Metabolism</em>. https://doi.org/10.1016/j.molmet.2019.09.013
Vancouver
Giroud‐Gerbetant J, Joffraud M, Giner MP, Cercillieux A, Bártová S, Makarov MV, et al. A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor. Molecular Metabolism. 2019. doi:10.1016/j.molmet.2019.09.013.
BibTeX
@article{judith2019Areduc,
title = {A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor},
author = {Judith Giroud‐Gerbetant and Magali Joffraud and Maria Pilar Giner and Angelique Cercillieux and Simona Bártová and Mikhail V. Makarov and Ruben Zapata Perez and José L. Sánchez-García and Riekelt H. Houtkooper and Marie E. Migaud and Sofia Moco and Carles Cantó},
journal = {Molecular Metabolism},
year = {2019},
doi = {10.1016/j.molmet.2019.09.013},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The FASEB Journal 2021
Open access · CC-BY
Reduced nicotinamide mononucleotide is a new and potent NAD + precursor in mammalian cells and mice
Nutrients 2022
Open access · CC-BY
Nicotinamide Riboside and Dihydronicotinic Acid Riboside Synergistically Increase Intracellular NAD+ by Generating Dihydronicotinamide Riboside
Nutrients 2023
Open access · CC-BY
Defining NAD(P)(H) Catabolism
Drug Design Development and Therapy 2026
Open access · CC-BY
Restorin® NR is a Highly Efficient NAD+ Precursor
Nutrients 2022
Open access · CC-BY
Supplementation with NAD+ and Its Precursors to Prevent Cognitive Decline across Disease Contexts
Drug design, development and therapy 2026
Open access · OA